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Essentials
• The rs773902 SNP results in differences in platelet pro-
tease-activated receptor (PAR4) function.
• The functional consequences of rs773902 were analyzed
in human platelets and stroke patients.
• rs773902 affects thrombin-induced platelet function,
PAR4 desensitization, stroke association.
• Enhanced PAR4 Thr120 effects on platelet function are
blocked by ticagrelor.
Summary. Background: F2RL3 encodes protease-activated
receptor (PAR) 4 and harbors an A/G single-nucleotide
polymorphism (SNP) (rs773902) with racially dimorphic
allelic frequencies. This SNP mediates an alanine to thre-
onine substitution at residue 120 that alters platelet PAR4
activation by the artificial PAR4-activation peptide
(PAR4-AP) AYPGKF. Objectives: To determine the func-
tional effects of rs773902 on stimulation by a physiological
agonist, thrombin, and on antiplatelet antagonist activ-
ity. Methods: Healthy human donors were screened and
genotyped for rs773902. Platelet function in response to
thrombin was assessed without and with antiplatelet antag-
onists. The association of rs773902 alleles with stroke was
assessed in the Stroke Genetics Network study. Results:
As compared with rs773902 GG donors, platelets from
rs773902 AA donors had increased aggregation in response
to subnanomolar concentrations of thrombin, increased
granule secretion, and decreased sensitivity to PAR4 desen-
sitization. In the presence of PAR1 blockade, this genotype
effect was abolished by higher concentrations of or longer
exposure to thrombin. We were unable to detect a genotype
effect on thrombin-induced PAR4 cleavage, dimerization,
and lipid raft localization; however, rs773902 AA platelets
required a three-fold higher level of PAR4-AP for receptor
desensitization. Ticagrelor, but not vorapaxar, abolished
the PAR4 variant effect on thrombin-induced platelet
aggregation. A significant association of modest effect was
detected between the rs773902 A allele and stroke. Conclu-
sion: The F2RL3 rs773902 SNP alters platelet reactivity to
thrombin; the allelic effect requires P2Y12, and is not
affected by gender. Ticagrelor blocks the enhanced reactiv-
ity of rs773902 A platelets. PAR4 encoded by the rs773902
A allele is relatively resistant to desensitization and may
contribute to stroke risk.
Keywords: blood platelets; genetic variation; receptors;
stroke; thrombin.
Introduction
Human platelets express two thrombin receptors, pro-
tease-activated receptor (PAR) 1 and PAR4 [1,2].
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Comparatively less research has been performed on
PAR4, perhaps because it was shown early that PAR1
had a higher affinity for thrombin [3–5]. However, work
from the Kuliopolos laboratory in 2000 demonstrated
that platelet PAR1 mediates a rapid but transient platelet
calcium signaling response to thrombin, whereas PAR4
mediates a slower, sustained rise, producing the majority
of the calcium response [6]. PAR4 also plays a more
important role in thrombin generation than PAR1 [7]. As
compared with platelets from white individuals, platelets
from black individuals are hyper-reactive when stimulated
with the AYPGKF activation peptide (AP) that specifi-
cally stimulates PAR4 [8–10]. Genome-wide approaches
identified a G/A single-nucleotide polymorphism (SNP) in
the gene encoding PAR4 (F2RL3), rs773902, that
accounted for ⁓ 50% of the racial variation in PAR4
activity [9]. The G/A SNP of rs773902 results in either an
alanine (Ala) or threonine (Thr), respectively, at posi-
tion 120 in the second transmembrane domain, with the
Thr-containing variant being more common in blacks
than in whites (allelic frequencies of 63% and 19%,
respectively [9]). The reasons for the differences in signal-
ing and kinetics between PAR1 and PAR4 and between
PAR4-Ala120 and PAR4-Thr120 are incompletely under-
stood, in part because of a lack of suitable reagents and a
murine model. Thus, the naturally occurring and common
functional PAR4-Ala120Thr genetic variant provides a
unique opportunity to gain a deeper understanding of
PAR biology and PAR1–PAR4 relationships.
Although platelet activation with PAR4-AP is depen-
dent on the rs773902 polymorphism, it is important to
characterize the thrombin response, for multiple reasons.
First, thrombin is the major in vivo physiological agonist
for PAR4, and AYPGKF is an artificial sequence that
does not occur in vivo [11]; furthermore, PAR signaling
can differ between thrombin APs and PAR-APs [12].
PAR-APs are used at micromolar or milimolar concentra-
tions, and do not allow assessment of relevant thrombin
concentrations for PAR activation. Second, because
thrombin functions as a platelet agonist through both
platelet PAR4 and PAR1 [13], and because PAR4 has
been shown to heterodimerize with PAR1 [13], it is criti-
cal to characterize thrombin-induced PAR4 signaling in
human platelets expressing both PAR4 and PAR1.
Finally, acute coronary syndrome patients who are
homozygous A for rs773902 showed less bleeding in a
clinical trial of the PAR1 blocker vorapaxar [14], but a
direct effect of the PAR4 variant on platelets inhibited
with vorapaxar has not been studied.
The goals of the current study were to assess the effects
of the PAR4 variant on stimulation by the physiological
agonist thrombin, the actions of common antiplatelet
agents, and the risk of in vivo thrombotic events. We now
report the PAR4-Ala120Thr variant regulates low-dose
thrombin-induced platelet aggregation, and that the
Thr120 isoform is relatively resistant to desensitization. In
addition, we report an effect of the rs773902 genotype on
the risk of stroke.
Materials and methods
Subject recruitment and genotyping
Healthy human donors aged between 21 years and
60 years of self-identified race from the greater Philadel-
phia area were screened and genotyped for rs773902
(Fig. S1) in F2RL3 with the TaqMan SNP Genotyping
Assay (Life Technologies, Carlsbad, CA, USA). Because
the rs773902 A allele is less common in the general popu-
lation but more common in blacks than in whites, we
recruited more blacks than whites (we screened 109 black
donors and 75 white donors). The exclusion criteria are
shown in Fig. 1. Of the 184 screened donors, 17 blacks
and 16 whites met the inclusion criteria and were avail-
able to be recalled for ex vivo platelet studies for the
duration of the study.
Platelet aggregation, activation, and desensitization
Washed platelets were prepared and adjusted to
2 9 108 platelets mL–1 in Tyrode’s buffer (137 mM NaCl,
2.7 mM KCl, 0.485 mM NaH2PO4, 12 mM NaHCO3,
25 mM HEPES, 1 mM MgCl2, 2 mM CaCl2, 0.1% glucose,
0.35% bovine serum albumin, pH 7.35) as previously
described [8,15]. Platelet aggregation was measured by use
of a PAP-8E Aggregometer with 0.5 mg mL1 arachi-
donic acid (Bio/Data Corporation, Horsham, PA, USA),
a-thrombin (1 nM = 0.1 U mL1; Enzyme Research Lab-
oratories, South Bend, IN, USA), PAR1-AP (SFLLRN),
and PAR4-AP (AYPGKF) (GL Biochem, Shanghai,
China). ATP release from washed platelets was measured
with a Chronolog Model 700 aggregometer (Chrono-Log,
Havertown, PA, USA), according to the manufacturer’s
instructions. P-selectin expression and calcium mobiliza-
tion were measured by flow cytometry as previously
described [10,16].
Desensitization was performed as previously described
[17–19]; washed platelets were incubated with 100–300 lM
PAR4-AP or 10 lM PAR1-AP in the presence of 0.5 lM
prostaglandin I2 for 30 min, and this was followed by
aggregometry with PAR4-AP or PAR1-AP.
PAR4 variant studies in heterologous cell lines
For PAR4 cleavage quantification, COS7 cells from the
American Type Culture Collection (Manassas, VA, USA)
were transfected with pCMV-3FLAG-PAR4-Ala120 or
PCMV-3FLAG-PAR4-Thr120 expression vectors vali-
dated by sequencing with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). Cells were harvested 24 h later, incu-
bated with thrombin for 5 min, 10 min, or 20 min, and
analyzed with a monoclonal anti-FLAG M2-fluorescein
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isothiocyanate antibody (Sigma-Aldrich, St Louis, MO,
USA) by the use of flow cytometry.
Bioluminescence resonance energy transfer (BRET)
HEK293 cells (1 9 105) were transfected with donor plas-
mid HA-PAR1-Luc or HA-P2Y12-Luc and increasing
amounts (0–1 lg) of acceptor plasmid (PAR4-120T-green
fluorescent protein [GFP] or PAR4-120A-GFP), and
stimulated with 10 nM a-thrombin for 10 min; this was fol-
lowed by the addition of 5 lM luciferase substrate (Coelen-
terazine 400a; Biotium, Hayward, CA, USA). Both PAR4
constructs were phenylalanine at residue 296. Emission was
detected with a Perkin Elmer Victor 3 plate reader
equipped with the appropriate BRET2 filter set. The BRET
signal was calculated as the ratio of emission at 515 nm to
emission at 410 nm minus the BRET in the absence of
GFP, as previously described [20–22].
Platelet lipid raft fractionation
Platelet lipid raft fractionation was performed as
described previously [23]. Untreated or stimulated (1 nM
thrombin) washed platelets were lysed, fractionated on a
5–30% sucrose gradient, and centrifuged at 200 000 9 g
for 18 h. Twelve equal fractions were collected, blotted
on a nitrocellulose membrane, and immunoblotted for
GM1 with Cholera Toxin B subunit (Sigma-Aldrich) or
anti-PAR4 14H6 [24].
Antagonist studies
Washed platelets were incubated with various concentra-
tions of the PAR1 inhibitor vorapaxar (Axon Medchem,
Reston, VA, USA), the PAR4 inhibitor BMS-986120
(Cayman Chemical, Ann Arbor, MI, USA), the P2Y12
inhibitors ticagrelor (Selleckchem, Houston, TX, USA) or
2-methylthioadenosine 50-monophosphate triethylammo-
nium salt hydrate (MeSAMP) (Sigma Aldrich), or the
cyclooxygenase inhibitor acetylsalicylic acid (ASA)
(Sigma-Aldrich), and maximal aggregation or calcium
mobilization was measured.
Stroke association study
Genotype and phenotype data were downloaded from the
Stroke Genetics Network (SiGN) study, containing
> 11 000 individuals from the National Center for
Biotechnology Information (NCBI) repository via the
NCBI database of Genotypes and Phenotypes [25]. The
SiGN is a large international collaboration designed to
detect genetic variants that predispose to subtypes of
ischemic stroke. Stroke status was defined by use of the
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19 failed AA aggregation





37 not able to be recalled
33 eligible subjects
Fig. 1. Subject recruitment and exclusion criteria. Healthy subjects were recruited and genotyped for rs773902. Written informed consent was
obtained from all participants with the approval of the Institutional Review Board of Thomas Jefferson University in Philadelphia, PA. This
flow diagram illustrates who was excluded from recall for the laboratory platelet studies. Failure to aggregate in response to arachidonic acid
was assumed to reflect non-steroidal anti-inflammatory drug use; ‘healthy’ was arbitrarily defined as the use of no more than one prescription
medication not known to affect platelet function; 37 were lost to follow-up after genotyping or otherwise not able to be recalled. Of the 33 eli-
gible subjects identified during the 3-year study, at least 20 were available for recall at any given time.
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scale [26]. rs773902 genotypes were extracted with PLINK
v1.07 [27]. Because the control population was exclusively
white (Ncontrol = 832) and the prevalence of the PAR4
variant differs by race [9], only data from the self-identi-
fied white cases (Ncases = 7338) were used, to avoid con-
founding with race. Among these cases, 6255 had
rs773902 genotype information (Table S1). Each TOAST
subgroup of the SiGN was analyzed for overall stroke
risk. We employed multivariate logistic regression models
for stroke outcome, and included both categorical and
continuous variables as potential contributors to stroke
risk. The rs773902 A allele was considered to be the risk
allele in a dominant model (heterozygous AG or homozy-
gous AA), a recessive model (homozygous AA) and an
additive model (A allele copy number) after controlling
for the stroke risk contributions of age, gender, hyperten-
sion, smoking, and diabetes status. We also examined
models that included an interaction effect between dia-
betes and genotype for the impact on stroke risk, because
of prior reports indicating a relationship between diabetes
and PAR4 [28], and our finding of an interaction between
genotype and diabetes status.
Results
Platelet aggregation in response to thrombin is enhanced by
the rs773902 AA genotype
Healthy donors were recruited, genotyped, and recalled
for ex vivo platelet studies. Prior work with 154 donors
[9] and additional preliminary studies showed that
heterozygotes have an intermediate phenotype for platelet
functional assays, so platelet function comparisons were
limited to subjects homozygous for rs773902 AA or GG,
encoding Thr/Thr and Ala/Ala, respectively (Fig. 1). As
expected, there were more self-identified blacks with the
rs773902 AA genotype. There were no significant differ-
ences in age, gender, body mass index or hematological
parameters between the two study groups (Table 1).
Thrombin dose–response curves demonstrated that pla-
telet aggregation was initiated at ~ 0.3 nM thrombin, and
that platelets from subjects with the rs773902 AA genotype
had a leftward-shifted dose–response curve relative to sub-
jects with the rs773902 GG genotype (P = 0.022; Fig. 2A,
B, solid lines). The concentration of thrombin required
to produce 50% maximal aggregation (EC50) was
significantly lower for platelets from rs773902 AA homozy-
gotes than for platelets from rs773902 GG homo-
zygotes (0.41  0.02 nM and 0.49  0.02 nM, respectively,
P < 0.001). Because there were more females in the GG
genotype group, additional analyses were performed and
showed no gender effect on thrombin response (Fig. 2C).
In addition, the genotype effect on the thrombin dose–
response curves did not vary by race (Fig. 2D,E). The num-
ber of platelet surface PARs did not differ by genotype
(Fig. S2). When PAR-APs were used, an even greater effect
of genotype was observed (Fig. S3), presumably because
thrombin-induced activation of PAR1 shifts the agonist
dose–response curve further leftward for rs773902 GG
homozygous platelets, and a PAR1-mediated shift does not
occur with PAR4-AP. Thus, as compared with rs773902
GG homozygous platelets, rs773902 AA homozygous pla-
telets show enhanced platelet aggregation in response to
thrombin regardless of gender or race.
PAR4–PAR1 interaction during low-concentration thrombin-
induced platelet aggregation
Because PAR4 has a lower affinity for thrombin than
does PAR1 [3,5,29], it has generally been thought that
PAR4 activation requires a substantially higher thrombin
concentration [4]. However, the data in Fig. 2 obtained
by the use of human platelets with PAR4 variants imply
an effect of PAR4 at low thrombin concentrations. Con-
sequently, we tested the contribution of PAR1 and PAR4
to thrombin stimulation following inhibition with vora-
paxar and BMS-986120, respectively. We found that
400 nM BMS-986120 fully inhibited PAR4-AP aggrega-
tion in both rs773902 A genotype (Fig. S4A) and G geno-
type subjects (data not shown). Neither BMS-986120 nor
vorapaxar had an effect on activation of the non-targeted
receptor by peptides (Fig. S4B,C).
Inhibition of PAR4 with the PAR4-specific BMS-
986120 compound shifted the thrombin dose–response
Table 1 Subject demographics
AA (n = 15) GG (n = 18) P-value
Age (years), mean  SD 41  14 39  13 0.51*
Female (%) 47 83 0.06†
Black race (%) 80 28 0.005†
BMI (kg m2), mean  SD 30  8 29  6 0.49*
Hb (g dL1), mean  SD 11.5  1.6 11.9  1.3 0.49*
MVP (fL), mean  SD 10.1  1.8 10.1  1.4 0.98*
WBC count (9 1000 lL1), mean  SD 5.5  1.5 5.8  1.6 0.57*
Platelet count (9 1000 lL1), mean  SD 293.5  68 321.7  85 0.31*
BMI, body mass index; Hb, hemoglobin; MVP, mean platelet volume; SD, standard deviation; WBC, white blood cell. Complete blood cell
counts were obtained with a Hemovet 950FS (Drew Scientific Group, Miami Lakes, FL, USA). *Student’s t-test. †Fisher’s exact t-test.
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Fig. 2. Thrombin dose–response curves for aggregation of rs773902 AA and GG platelets. (A) Washed platelets were treated with the indicated
concentrations of thrombin. Representative aggregation traces for rs773902 GG homozygotes (left) and rs773902 AA homozygotes (right) are
shown. (B–E) Maximal aggregation ( standard error of the mean) assessed at a 15-min fixed time point. (B) Combined data for all subjects
allowing comparisons among aggregations with no inhibitor (solid lines), protease-activated receptor (PAR) 4 inhibition with 400 nM BMS-
986120 (dotted line), and PAR1 inhibition with 100 nM vorapaxar (dashed line). Genotype curves were not significantly different after BMS-
986120 (P = 0.69) or vorapaxar (P = 0.53) addition. (C) Thrombin dose response by gender. (D, E) Effect of race on thrombin dose response
by rs773902 GG (D) and AA (E) genotypes. Note that the numbers of white rs773902 AA subjects are small because they represent only ~ 4%
of the population, and the numbers of black rs773902 GG subjects are small because they represent only ~ 6% of the population. Genotype
differences between thrombin dose–response curves were measured with repeated-measures ANOVA. [Color figure can be viewed at wileyonlinelib
rary.com]
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curves of both genotypes to the right (Fig. 2B, dotted
lines; P < 0.0001). In the absence of PAR4 signaling,
PAR1-induced platelet aggregation began at ~ 0.5 nM
thrombin and the EC50 increased to ~ 0.7 nM. These data
indicate that PAR4 contributes to thrombin-induced pla-
telet aggregation at low thrombin concentrations in the
range of ~ 0.4 nM to ~ 0.8 nM (i.e. the difference between
the solid and dotted lines in Fig. 2B). There was no sig-
nificant difference between the two genotype curves for
the PAR1-mediated thrombin dose response.
Inhibition of PAR1 with vorapaxar caused an even
greater rightward shift in the thrombin dose–response
curves (Fig. 2B, dashed lines; P < 0.0001). In the absence
of PAR1 signaling, PAR4-induced platelet aggregation
began at ~ 0.8 nM thrombin and the average EC50
increased to ~ 1.0 nM. Although there was no statistically
significant difference between thrombin dose–response
curves obtained with vorapaxar treatment, there is a sug-
gestion that the genotype effect may persist in the 0.8–
1.0 nM thrombin range. Finally the data in Fig. 2 also
suggest that maximal platelet aggregation may be greater
for PAR4 alone than for PAR1 alone (~ 72% versus
~ 57%).
Because glycoprotein (GP) Iba can also bind thrombin
and activate PAR1 [30], we considered whether GPIba
was contributing to the low-dose thrombin response. SZ2,
a GPIba-specific mAb that blocks thrombin binding
[31,32], had no effect on rs773902 AA or GG aggregation
at 0.45 nM thrombin (Fig. S5), indicating that GPIba
does not contribute to the low-dose thrombin response.
Collectively, these data indicate that PAR4 contributes to
platelet aggregation at low thrombin concentrations.
The kinetic effect of rs773902 on platelet aggregation in
response to thrombin
It has recently been shown that Gq and G13 activation is
increased by purified PAR4-Thr120 as compared with
purified PAR4-Ala120, peaking at ⁓ 2 min; thereafter, the
genotype effect is lost [33]. Therefore, we determined
whether there were genotype effects on time-dependent
platelet aggregation. In the absence of PAR inhibitors,
the genotype difference persisted for 15 min at 0.4 nM
and 0.5 nM thrombin, but was lost at 0.6 nM thrombin
(Fig. 3A). Inhibition of PAR4 blocked the genotype dif-
ference at all thrombin concentrations (Fig. 3B). When
PAR1 was blocked, there was an apparent genotype effect
only at low concentrations (< 1.2 nM) and at early time
points (~ 200–400 s) (Fig. 3C), an effect that was not
observed at the fixed 15-min time point in Fig. 2B.
Genotypic differences in thrombin-induced feedback
mechanisms of platelet activation
Both activation of PAR4 and activation of PAR1 induce
granule release as a feedback mechanism to enhance and
stabilize platelet aggregation, with PAR1 producing rever-
sible aggregation, and PAR4 producing irreversible aggre-
gation [6,17,34]. We therefore considered whether the
PAR4 variant might alter granule release. As compared
with platelets from rs773902 GG donors stimulated with
low concentrations of thrombin, platelets from rs773902
AA donors showed a small increase in a-granule release
(P = 0.044; Fig. 4A) and more substantial dense granule
release (P = 0.02 at 1 nM thrombin; Fig. 4B).
Platelets with the F2RL3 AA genotype are resistant to
desensitization
We considered a number of potential molecular mecha-
nisms that might account for the PAR4-Ala120
Thr-dependent difference in thrombin-induced platelet
aggregation. First, COS7 cells were transfected with N-
terminally FLAG-tagged PAR4 expression plasmids for
each variant, but no significant difference was observed in
thrombin cleavage of the two isoforms (Fig. 5A). Second,
using HEK293 cells transiently expressing PAR1 and
PAR4, we did not observe differences in heterodimeriza-
tion between the rs773902 AA and rs773902 GG variants
as measured by BRET fluorescence (Fig. 5B). Third,
because residue 120 of PAR4 faces externally in the sec-
ond transmembrane region, and a Thr (polar) substitu-
tion for Ala (non-polar) may be more likely to interact
with the lipid bilayer, we considered whether the variant
altered localization in lipid microdomains of platelets
from different donors. Lipid raft fractions were probed
by immunoblots for PAR4, but neither variant was
observed to localize in the raft fraction (Fig. 5C). Finally,
PAR4 has been shown to abrogate PAR1 signaling desen-
sitization [35], but the effect of the F2RL3 rs773902 geno-
type has not been considered. As shown in Fig. 5D,E,
rs773902 GG platelets were fully desensitized with 100 lM
PAR4-AP, whereas rs773902 AA platelets were minimally
affected (P = 0.03 and P = 0.34, respectively). As com-
pared with rs773902 GG platelets, rs773902 AA platelets
required a three-fold increased concentration of PAR4-
AP for complete desensitization (Fig. 5F; P < 0.001).
Desensitization of PAR1 or PAR4 had no significant
effect on response to the other PAR receptor (Fig. S6).
Although there are limitations to the cell line assays
(Fig. 5A,B), the simplest interpretation of these data is
that the rs773902 genotype difference in thrombin sensi-
tivity may be mediated by receptor desensitization and
trafficking.
Pharmacogenetic effect of the Ala120Thr variant on
antiplatelet antagonists
The current management of cardiovascular disease is
based largely on clinical studies that have included pri-
marily white subjects who have a low (~ 20%) frequency
of the rs773902 A allele [9], and we next sought to
© 2018 International Society on Thrombosis and Haemostasis
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Fig. 3. Kinetics of thrombin-induced aggregation of rs773902 AA and GG platelets. Platelet aggregation is shown as mean  standard error of
the mean at different fixed thrombin concentrations but plotted over time. Sampling was performed every 0.5 s. [Color figure can be viewed at
wileyonlinelibrary.com]
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address whether there is an ex vivo pharmacogenetic
effect of rs773902 on antiplatelet drugs. Because of
interindividual differences in thrombin EC50s (even
within genotype), a thrombin dose–response investigation
was performed on each donor’s platelets. Platelets from
both genotypes were subsequently incubated with varying
concentrations of the PAR1 inhibitor vorapaxar, and
stimulated with the concentration of thrombin required to
cause 80% aggregation (EC80), which averaged 0.59 nM
in the 16 donors. There was no significant difference by
genotype in the vorapaxar dose response of aggregation
inhibition when stimulation was performed with an EC80
amount of thrombin (Fig. 6A; P = 0.35). In contrast,
when platelets were stimulated with a fixed dose of 1 nM
thrombin, the vorapaxar IC50 was 1.8-fold higher for pla-
telets from rs773902 AA donors than for platelets from
rs773902 GG donors (Fig. 6B; P < 0.0001). These data
are consistent with the vorapaxar effect shown in Figs 2B
and 3C.
As ADP is a critical second messenger released from
dense granules, the greater ATP release observed in
rs773902 AA platelets (Fig. 4B) raised the possibility that
these platelets may be less responsive to P2Y12 inhibitors.
Platelets from both genotypes were incubated with
varying concentrations of the non-competitive P2Y12 inhi-
bitor ticagrelor, and stimulated with either an EC80
amount of thrombin determined for each individual sub-
ject, or with a fixed dose of 1 nM thrombin. There was no
significant difference in sensitivity to ticagrelor either at
an EC80 concentration of thrombin (Fig. 6C) or at 1 nM
thrombin (Fig. 6D). This indicates that P2Y12 function is
important for the rs773902 genotype effect at sub-
nanomolar thrombin concentrations. In contrast, the
IC50 of the competitive P2Y12 antagonist (MeSAMP) for
1 nM thrombin-induced platelet aggregation was six-fold
higher for platelets from rs773902 AA donors than for
platelets from rs773902 GG donors (Fig. S7A). The
rs773902 genotype had no effect on the ability of
cyclooxygenase inhibition by ASA to attenuate thrombin-
induced platelet aggregation (Fig. S7B).
F2RL3 variant association with stroke risk
Public datasets with genome-wide genotype data and
atherothrombotic outcomes were examined to determine
whether individuals with the F2RL3 rs773902 A allele
had an increased risk of having platelet-related ischemic
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Fig. 4. Thrombin-induced granule secretion. Washed platelets were stimulated with the indicated concentrations of thrombin. (A) P-selectin
was quantified as the percentage of maximal mean fluorescence intensity (MFI) by flow cytometry relative to the MFI with the highest concen-
tration of thrombin. (B) ATP release was measured with a Chronolog aggregometer. [Color figure can be viewed at wileyonlinelibrary.com]
Fig. 5. Assessment of potential mechanistic effects of rs773902 genotypes. (A) COS7 cells were transfected with FLAG-tagged protease-acti-
vated receptor (PAR) 4 expression vectors for rs773902 A or rs773902 G, and incubated with varying concentrations of thrombin. Loss of sur-
face FLAG expression was detected by flow cytometry as a percentage of baseline (% maximum  SEM). (B) HEK293 cells were transfected
with HA-PAR1-rLuc (0.5 lg) and PAR4-120Τ-GFP (PAR4-TF) or PAR4-120A-GFP (PAR4-AF) (0–1 lg), treated with a-thrombin (10 nM),
and analyzed for GFP expression, luciferase activity, and bioluminescence resonance energy transfer (BRET). The data are from three indepen-
dent experiments in which all points were analyzed by global fit to a hyperbolic fit to determine the maximum BRET (BRETmax: Ala120
0.19  0.05 versus Thr120 0.22  0.03). The specificity of the interactions determined by BRET were confirmed with rhodopsin (data not
shown). (C) Platelet lipid raft isolation and immunoblotting for PAR4 and GM1. A representative blot is shown, as well as combined data
indicating the percentage of the total protein per fraction (% total  SEM). (D) Representative tracings for rs773902 GG (left) and AA (right)
platelets desensitized with 100 lM PAR4-AP and stimulated with 200 lM PAR4-AP. (E) Combined desensitization data for all subjects (%
maximum aggregation  SEM). (F) rs773902 AA platelets were desensitized with 100 lM, 200 lM or 300 lM PAR4-AP, and stimulated with
200 lM PAR4-AP (% maximum aggregation  SEM). AP, activation peptide; GFP, green fluorescent protein; MFI, mean fluorescence
intensity; TF, PAR4 plasmid with threonine (T) at residue 120 and phenylalanine (F) at residue 296 AF, PAR4 plasmid with alanine (A) at
residue 120 and phenylalanine (F) at residue 296. [Color figure can be viewed at wileyonlinelibrary.com]
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that included both relevant clinical outcome data and
rs773902 genotype data [25]. Table S1 shows the number
of patients by genotype and stroke subtype, totaling 6255.
Association analysis demonstrated strong positive associa-
tions with stroke risk for the correlates male gender, older
age (≥ 75 years), smoking, hypertension and diabetes
across the various models, so we analyzed the rs773902 A
allele contribution to risk after controlling for these fac-
tors as well as an interaction for diabetes status. Table 2
shows that the rs773902 A allele was associated with an
increased stroke risk (all TOAST categories) (odds ratio
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Fig. 6. Effect of the rs773902 genotype and protease-activated receptor 1 and P2Y12 inhibition on thrombin-induced platelet aggregation. (A,
B) Washed platelets were incubated with varying concentrations of vorapaxar (VPX), and stimulated with (A) a thrombin EC80 (AA – range
0.45–0.6 nM; mean: 0.54 nM; GG – range 0.45–0.55 nM; mean: 0.49 nM) or (B) 1 nM thrombin, and percentage maximum aggregation  stan-
dard error of the mean was recorded. (C, D) A similar experiment was performed with the allosteric P2Y12 inhibitor ticagrelor, with (C) throm-
bin EC80 or (D) 1 nM thrombin. IC50s were calculated for ticagrelor and VPX for rs773902 genotypes (mean  standard deviation). A
thrombin concentration of 1 nM was chosen because this was the lowest concentration causing the maximal aggregation plateau (Fig. 2B), and
would be expected to be sensitive to the effects of ADP. P-values were determined with Student’s t-test (B) and with an extra sum-of-squares
F-test for the differences in IC50s. [Color figure can be viewed at wileyonlinelibrary.com]
Table 2 Relationship of rs773902 A with stroke; dose-dependent
model*
Stroke subset Odds ratio (95% CI) P-value
All stroke 1.166 (1.006–1.356) 0.044
Cardioembolic 1.146 (0.954–1.379) 0.146
Large-artery atherosclerosis 1.232 (0.998–1.524) 0.053
Small-vessel occlusion 1.146 (0.946–1.390) 0.164
Other 1.105 (0.934–1.309) 0.248
CI, confidence interval. *A dose-dependent model is presented here
because the in vitro platelet function studies showed a dosage effect
of the rs773902 A allele.
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confidence interval [CI] 1.006–1.356, P = 0.044); in addi-
tion, large-artery stroke showed an odds ratio increase of
1.232 for each additional copy of A (CI 0.997–1.524,
P = 0.053). A full listing of the regression models and
results is given in Table S2, and shows that the rs773902
A allele demonstrated a modest but consistent pattern of
trending for stroke risk across the three dominant, reces-
sive or dose-dependent genetic models.
Discussion
The clinical and functional importance of PAR4 has been
less well evaluated than that of PAR1. In this study, we
used a common and naturally occurring PAR4 functional
variant to better define the role of PAR4 in thrombin-
induced platelet activation. The major findings of our
investigations are as follows: (i) the F2RL3 rs773902 SNP
alters in vitro platelet reactivity at subnanomolar concen-
trations of thrombin and at early time points, but geno-
type differences are overcome at higher thrombin
concentrations and longer time points – this indicates that
both PAR1 and PAR4 contribute to a subnanomolar
thrombin response; (ii) the enhanced rs773902 AA reac-
tivity is eliminated by P2Y12 antagonism with ticagrelor,
and, at low thrombin concentrations, by vorapaxar; and
(iii) rs773902 AA platelets are more resistant to receptor
desensitization. In addition, we provide evidence that the
rs773902 A allele is associated with the risk of stroke in
white patients. Like other functional genomic variants
[36,37], rs773902 has the same in vitro effect regardless of
self-identified race (Fig. 2D,E). As the frequency of the
rs773902 A allele is more than three times higher in
blacks of Sub-Saharan East African ancestry than in
whites, the allele frequency may contribute to racial dis-
parities in the outcomes of cardiovascular disease.
Most studies using heterologous cell systems have
shown that one to two orders of magnitude higher throm-
bin concentrations are required to induce signaling
through PAR4 than signaling through PAR1 [3,4]. These,
coupled with the lack of a high-affinity binding site for a-
thrombin [4], have supported the idea that PAR4 cleavage
and activation occur only at high thrombin concentra-
tions. Using human platelets, we found that 0.4–0.5 nM
thrombin achieves 50% aggregation (EC50) of washed
platelets, which is a finding similar to that reported by
Leger et al. [13]. Importantly, the significantly different
EC50s between the two PAR4 variants indicate a role of
PAR4 in platelet aggregation at the steep part of the
thrombin dose–response curve. When PAR1 is inhibited
by vorapaxar, the thrombin dose–response and time–re-
sponse data support a persistent genotype effect only at
early time points with low concentrations of thrombin
(Figs 2B and 3C). These thrombin-stimulated platelet
aggregation data are consistent with the faster G-protein
binding kinetics demonstrated with purified PAR4 variant
proteins preincubated with PAR4-AP [33]. Although
in vivo concentrations of thrombin in the local microenvi-
ronment of a forming thrombus are unknown, it is
believed that there is a concentration gradient of agonists
from the tightly packed core of the thrombus to the outer
shell [38–42]. One can imagine that, as the thrombin con-
centrations decrease along this gradient, there is a region
where thrombin will activate rs773902 AA platelets, but
not rs773902 GG platelets, leading to differences in the
size and structure of the thrombus.
The genotype effect on the agonist dose response
appeared to be greater for PAR4-AP than for thrombin
(Figs 2B and S2). The simplest explanation is that throm-
bin activation of PAR1 induces a leftward shift in the
curve that overcomes the relative ‘hyporeactivity’ of
rs773902 GG platelets. However, other possible explana-
tions include different PAR4 conformations stabilized by
the tethered ligand as compared with the AP, which indi-
cates coupling to different G-proteins [12]. Differential
genotype-mediated dimerization with other G-protein-
coupled receptors could also result in different signaling
in response to the tethered ligand or AP.
Initial mechanistic studies showed similar surface
expression of PAR4, receptor cleavage, dimerization and
lipid raft localization between the two F2RL3 genotypes,
and no effect of GPIba, although deeper investigation into
these mechanisms may be warranted. However, significant
differences in PAR4 desensitization were observed. It is
well established that stimulation of a PAR in the presence
of an inhibitor of aggregation results in ‘desensitization’
of that receptor [43,44]. Such desensitization has been used
as a tool to uncouple PAR4 signaling from PAR1 signal-
ing in response to thrombin, and has been a valuable
approach for studying post-PAR cleavage signaling events
[13,35,45,46]. Although the exact mechanism of PAR
desensitization is not fully understood, it is thought to
involve a combination of post-translational modification
and internalization to prevent further downstream signal-
ing. It was recently shown that PAR4-Thr120–P2Y12 het-
erodimers mediate PAR4 internalization and enhanced
signaling in heterologous cell lines [47,48]. Because
secreted ADP enhances PAR-induced platelet signaling
and activation [49], we hypothesized that the Thr120 vari-
ant favors PAR4–P2Y12 heterodimer formation. Such a
mechanism would be consistent with our observed
increased dense granule release in PAR4-Thr120 platelets
(Fig. 4B), as well as the inability of the ADP competitive
inhibitor MesAMP to overcome the genotype effect of
low-dose thrombin activation (Fig. S7). Although coim-
munoprecipitation experiments showed increased PAR4–
P2Y12 heterodimerization in PAR4-Thr120-expressing
HEK293 cells, similar BRET studies did not demonstrate
a genotype effect (Figs S8 and S9). Perhaps our experi-
mental conditions did not support a BRET-identified
PAR4 variant effect, and additional work is needed to
address whether the Thr120 variant favors PAR4–P2Y12
heterodimer formation and to more accurately define a
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role for ADP and P2Y12 in the hyper-reactive PAR4-
Thr120 phenotype. Nevertheless, our data obtained with a
non-competitive P2Y12 inhibitor (ticagrelor) demonstrate
a functional (if not physical) interaction between PAR4
and P2Y12 that differs by PAR4 variant.
There are many genomic studies considering associa-
tions between vascular ischemic events and platelet gene
variants, but few of these were performed with a genotyp-
ing platform with good coverage of common variants in
PAR4. Our analysis of the SiGN cohort showed that
individuals bearing the rs773902 A allele had a pattern of
greater risk for ischemic stroke. Although our study is the
largest to date on the in vitro effects of thrombin on the
PAR4-Ala120Thr variant, a larger sample size would
enable consideration of other confounding genetic or
demographic variables. However, the small but significant
association between the rs773902 A allele and ischemic
stroke seen in the ~ 7000 stroke patients reported in our
study (Table 2) and the reduction in bleeding associated
with the rs773902 AA genotype seen in ~ 7000 ischemic
coronary patients receiving antiplatelet therapy [14] pro-
vide important support for the in vivo importance of this
genetic variant. Together with our functional data, these
clinical association signals warrant further study, includ-
ing of an rs773902–diabetes interaction.
The importance of understanding the physiological
effects of the common PAR4-A120T variant is under-
scored by the critical role of thrombin in platelet thrombus
formation and the recent interest in PAR4 inhibition as a
therapeutic strategy (e.g. BMS-986141 and BMS-986120)
[50–52]. Our results have demonstrated that the rs773902
genotype alters ex vivo thrombin-induced platelet reactiv-
ity, affects receptor desensitization, and is associated with
a modest stroke risk. These results have potential clinical
significance in atherothrombotic disease, in which the
PAR4 variant could modify ischemic or hemorrhagic out-
comes despite currently used antiplatelet agents. It will be
important for future antiplatelet clinical trials to test for
pharmacogenetic interactions with the PAR4 variant and
to develop antiplatelet therapies with good efficacy against
platelets expressing the rs773902 A allele (predominantly
black patients). PAR4 blockade may be beneficial in this
regard if the novel compounds are not sensitive to
rs773902 genotype effects in the presence of low-dose
thrombin-induced platelet reactivity. Alternatively, combi-
nation antiplatelet therapy that includes a non-competitive,
allosteric antagonist of P2Y12 may be beneficial.
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